SGMT vs. ZYME, PHAR, MLYS, PHAT, ORIC, ALXO, SVRA, CDMO, IGMS, and TRDA
Should you be buying Sagimet Biosciences stock or one of its competitors? The main competitors of Sagimet Biosciences include Zymeworks (ZYME), Pharming Group (PHAR), Mineralys Therapeutics (MLYS), Phathom Pharmaceuticals (PHAT), ORIC Pharmaceuticals (ORIC), ALX Oncology (ALXO), Savara (SVRA), Avid Bioservices (CDMO), IGM Biosciences (IGMS), and Entrada Therapeutics (TRDA). These companies are all part of the "pharmaceutical preparations" industry.
Zymeworks (NYSE:ZYME) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.
In the previous week, Sagimet Biosciences had 3 more articles in the media than Zymeworks. MarketBeat recorded 5 mentions for Sagimet Biosciences and 2 mentions for Zymeworks. Zymeworks' average media sentiment score of 0.91 beat Sagimet Biosciences' score of -0.44 indicating that Sagimet Biosciences is being referred to more favorably in the news media.
Sagimet Biosciences has a net margin of 0.00% compared to Sagimet Biosciences' net margin of -249.63%. Sagimet Biosciences' return on equity of -28.37% beat Zymeworks' return on equity.
Zymeworks received 270 more outperform votes than Sagimet Biosciences when rated by MarketBeat users. However, 100.00% of users gave Sagimet Biosciences an outperform vote while only 68.59% of users gave Zymeworks an outperform vote.
92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 1.2% of Zymeworks shares are owned by company insiders. Comparatively, 17.6% of Sagimet Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Sagimet Biosciences has lower revenue, but higher earnings than Zymeworks.
Zymeworks presently has a consensus price target of $12.67, indicating a potential upside of 49.37%. Sagimet Biosciences has a consensus price target of $39.20, indicating a potential upside of 635.46%. Given Zymeworks' stronger consensus rating and higher probable upside, analysts plainly believe Sagimet Biosciences is more favorable than Zymeworks.
Summary
Sagimet Biosciences beats Zymeworks on 10 of the 15 factors compared between the two stocks.
Get Sagimet Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SGMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sagimet Biosciences Competitors List
Related Companies and Tools
